Pharmacokinetics of Midazolam in Neonates Undergoing Extracorporeal Membrane Oxygenation

Background Although the pharmacokinetics of midazolam in critically ill children has been described, there are no such reports in extracorporeal membrane oxygenation. Methods The pharmacokinetics of midazolam and 1-hydroxy midazolam after continuous infusion (50–250 &mgr;g · kg−1 · h−1) were determined in 20 neonates undergoing extracorporeal membrane oxygenation. Patients were randomized into two groups: group 1 (n = 10) received midazolam extracorporeally (into the circuit), and group 2 received drug via central or peripheral access. Blood samples for determination of plasma concentrations were taken at baseline, 2, 4, 6, 12, 18, and 24 h, then every 12 h. Population pharmacokinetic analysis and model building was conducted using WinNonMix (Pharsight Corporation, Mountain View, CA). The 1-hydroxy midazolam/midazolam metabolic ratio was determined as a surrogate marker of cytochrome P450 3A activity. Results The parameter estimates (n = 19) were based on a one-compartment model with time-dependent change in volume of distribution. Volume (mean ± standard error) expanded monoexponentially from the onset of extracorporeal membrane oxygenation to a maximum value, 0.8 l ± 0.5 and 4.1 ± 0.5 l/kg, respectively. Consequently, plasma half-life was substantially prolonged (median [range]) from onset to steady-state: 6.8 (2.2–39.8) and 33.3 (7.4–178) h, respectively. Total body clearance was determined as (mean ± standard error) 1.4 ± 0.15 ml · kg−1 · min−1. The median metabolic ratio was 0.17 (0.03–0.9). No significant differences were observed between the two groups with respect to parameter estimates. Simulations of plasma concentration profiles revealed excess levels at conventional doses. Conclusions These results reveal significantly increased volume of distribution and plasma half-life in neonates receiving extracorporeal membrane oxygenation. Altered kinetics may reflect sequestration of midazolam by components of the extracorporeal membrane oxygenation circuit.

[1]  H. Mulla,et al.  Effects of neonatal extracorporeal membrane oxygenation circuits on drug disposition , 2000 .

[2]  H. Mulla,et al.  Plasma Concentrations of Midazolam in Neonates Receiving Extracorporeal Membrane Oxygenation , 2003, ASAIO journal.

[3]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[4]  R. Nelson,et al.  Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation , 1993 .

[5]  B. Roth,et al.  Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit , 1991, European Journal of Pediatrics.

[6]  J. Arnold,et al.  Changes in the pharmacodynamic response to fentanyl in neonates during continuous infusion. , 1991, The Journal of pediatrics.

[7]  D. Rosen,et al.  Fentanyl uptake by the scimed membrane oxygenator. , 1988, Journal of cardiothoracic anesthesia.

[8]  A. Lloyd-Thomas,et al.  Infusion of midazolam in paediatric patients after cardiac surgery. , 1986, British journal of anaesthesia.

[9]  T. Cresteil,et al.  Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. , 1997, European journal of biochemistry.

[10]  G. Tucker,et al.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. , 1999, British journal of clinical pharmacology.

[11]  J. Magny,et al.  Population pharmacokinetics of midazolam in neonates , 1994, Clinical pharmacology and therapeutics.

[12]  P. Steer,et al.  Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. , 1999, Anesthesiology.

[13]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[14]  D. Rosen,et al.  In vitro variability in fentanyl absorption by different membrane oxygenators. , 1990, Journal of cardiothoracic anesthesia.

[15]  A. Gill,et al.  Steady-State Plasma Concentrations of Midazolam in Critically Ill Infants and Children , 1996, The Annals of pharmacotherapy.

[16]  Lewis B. Sheiner,et al.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[17]  I. Patel,et al.  Increased volume of distribution prolongs midazolam half-life. , 1990, British journal of clinical pharmacology.

[18]  E. Orav,et al.  Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation. , 1990, Anesthesiology.

[19]  F. Mattheyse,et al.  The pharmacokinetics of midazolam in paediatric patients , 2004, European Journal of Clinical Pharmacology.

[20]  Meindert Danhof,et al.  Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers , 1992, Clinical pharmacology and therapeutics.

[21]  J. Beijnen,et al.  Population Pharmacokinetics of Ifosfamide and its Dechloroethylated and Hydroxylated Metabolites in Children with Malignant Disease , 2001, Clinical pharmacokinetics.

[22]  H. Mulla,et al.  Drug disposition during Extra Corporeal Membrane Oxygenation ECMO , 2001 .

[23]  G. Koren,et al.  Sequestration of fentanyl by the cardiopulmonary bypass (CPBP) , 2004, European Journal of Clinical Pharmacology.

[24]  É. Jacqz-Aigrain,et al.  Pharmacokinetics of midazolam in critically ill neonates , 2004, European Journal of Clinical Pharmacology.

[25]  J G Reves,et al.  Midazolam: Pharmacology and Uses , 1985, Anesthesiology.

[26]  S L Shafer,et al.  Pharmacokinetics of Computer‐controlled Alfentanil Administration in Children Undergoing Cardiac Surgery , 1995, Anesthesiology.

[27]  J. Dundee,et al.  A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. , 1988, British journal of anaesthesia.

[28]  M. Hynynen Binding of fentanyl and alfentanil to the extracorporeal circuit. , 1988, Acta anaesthesiologica Scandinavica.

[29]  É. Jacqz-Aigrain,et al.  Pharmacokinetics of midazolam during continuous infusion in critically ill neonates , 2004, European Journal of Clinical Pharmacology.

[30]  J. Chong,et al.  The addition of intrathecal sufentanil and fentanyl to bupivacaine for caesarean section. , 1998, Singapore medical journal.

[31]  S. Shafer,et al.  Population Pharmacokinetics of Midazolam Administered by Target Controlled Infusion for Sedation following Coronary Artery Bypass Grafting , 1998, Anesthesiology.

[32]  G. Tucker,et al.  Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. , 2002, British journal of anaesthesia.

[33]  G. Koren,et al.  Preliminary Studies of the Effects of Extracorporeal Membrane Oxygenator on the Disposition of Common Pediatric Drugs , 1993, Therapeutic drug monitoring.

[34]  R. Nelson,et al.  Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation. , 1993, The Journal of thoracic and cardiovascular surgery.

[35]  W. Hop,et al.  Pharmacokinetics and metabolism of intravenous midazolam in preterm infants , 2001, Clinical pharmacology and therapeutics.

[36]  W. Trager,et al.  Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.

[37]  F. Reynolds,et al.  Extracorporeal circuit sequestration of fentanyl and alfentanil. , 1986, British journal of anaesthesia.

[38]  H. Mulla,et al.  In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation , 2000, Perfusion.